

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problems Mailbox.**

Fig. 1 ACA Activity Effect of Serum vs Fish Gelatin




FIGURE 1




FIGURE 2





FIGURE 3




FIGURE 4

Serum Crossreactivity of ACA 6626-403 Peptide




FIGURE 5




FIGURE 6

ACA ELISA of Purified Ab fr. Serum 6501




FIGURE 7

6501 G-Track of Random Clones

2nd Round 3rd Round 4th Round 5th Round c1c2




FIGURE 8




FIGURE 9

Phage ELISA w/ 6501 Mollr Phage 11.9.93




FIGURE 10

Inhibition of (3B10)4 / 6501 Derived by 6501
Derived Peptide Monomer with 400 Diluted
Ser.6501




FIGURE 11

Inhibition of Cdl-2.3%Hu Ser.(no IgG) by
Modified Peptides 3G3 with 400x Diluted
Serum 6501




FIGURE 12

Inhibition of (3B10)4 / 6501 Derived by Truncated or Non-Truncated 3B10 with 400 Diluted Serum 6501




FIGURE 13

Inhibition of (3B10)4 / 6501 Derived by Alpha MeP 3B10 Monomer with 400 Diluted Serum 6501




FIGURE 14

Cross reactivity of peptide LJP 688 with aff-ACA

Cardiolipin/ β 2-GPI-coated plates




FIGURE 15

LJP 685-MTU-DABA-PEG (COMPOUND 36)




Figure 16

LJP 685-ATU-MTU-AHAB-TEG (COMPOUND 35)




Figure 17

DS-G3C Solution Structure

CLGVLA^KLC




Figure 18

Solution Structures of Lead ACA Peptides: Cyclic Nine Residue Peptides




Figure 19

Pharmacophore for binding to anti-cardiolipin antibodies, based on solution structure of DS3G3c (CLGVLA^KLC) and alanine scanning of this peptide




Figure 20A




Figure 20B

Inhibition of β_2 GP-1 by 6501-Derived Peptides with 350x Diluted Serum 6501




FIGURE 21

6701 Titration of CB2*-F:
(FITC)-GPCILLARDRCG-CO₂⁻




FIGURE 22

6501 Titration of CB2*-F:
(FITC)-GPCILLARDRCG-CO₂⁻




FIGURE 23

6501 Titration of CB2*-F:
(FITC)-GPCILLARDRCG-CO₂⁻




FIGURE 24

Displacement of CB2*-F from
6701 using 1.04 eq. of CB2*:
GPCILLARDRCG-CO₂⁻




FIGURE 25

CB2* Titration of CB2*-F/6701:
CB2*: GPCILLARDRCG-CO₂⁻




FIGURE 26

3B10 Titration of CB2*-F/6701:
3B10: AGPCLLLAPDRCPG-CO₂⁻




FIGURE 27




FIGURE 28




FIGURE 29




FIGURE 30




FIGURE 31




FIGURE 32